nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0374	0.0646	CbGbCtD
Paroxetine—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0356	0.0616	CbGbCtD
Paroxetine—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0299	0.0517	CbGbCtD
Paroxetine—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0284	0.0491	CbGbCtD
Paroxetine—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.027	0.0467	CbGbCtD
Paroxetine—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0261	0.0451	CbGbCtD
Paroxetine—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0253	0.0437	CbGbCtD
Paroxetine—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0249	0.0431	CbGbCtD
Paroxetine—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0241	0.0416	CbGbCtD
Paroxetine—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0238	0.0412	CbGbCtD
Paroxetine—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0222	0.0383	CbGbCtD
Paroxetine—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.0196	0.034	CbGbCtD
Paroxetine—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.0188	0.0326	CbGbCtD
Paroxetine—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.0188	0.0326	CbGbCtD
Paroxetine—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0183	0.0316	CbGbCtD
Paroxetine—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.0174	0.0301	CbGbCtD
Paroxetine—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0172	0.0298	CbGbCtD
Paroxetine—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.0168	0.029	CbGbCtD
Paroxetine—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0159	0.0275	CbGbCtD
Paroxetine—CYP2C9—Valsartan—type 2 diabetes mellitus	0.0154	0.0266	CbGbCtD
Paroxetine—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.0143	0.0247	CbGbCtD
Paroxetine—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.0137	0.0237	CbGbCtD
Paroxetine—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0131	0.0226	CbGbCtD
Paroxetine—CYP2C8—Losartan—type 2 diabetes mellitus	0.0126	0.0219	CbGbCtD
Paroxetine—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0126	0.0217	CbGbCtD
Paroxetine—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0125	0.0217	CbGbCtD
Paroxetine—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00965	0.0167	CbGbCtD
Paroxetine—ABCB1—Glyburide—type 2 diabetes mellitus	0.00936	0.0162	CbGbCtD
Paroxetine—CYP2C9—Losartan—type 2 diabetes mellitus	0.00882	0.0153	CbGbCtD
Paroxetine—ABCB1—Losartan—type 2 diabetes mellitus	0.00856	0.0148	CbGbCtD
Paroxetine—TACR1—peripheral nervous system—type 2 diabetes mellitus	0.00494	0.116	CbGeAlD
Paroxetine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00413	0.0967	CbGeAlD
Paroxetine—HTR2A—arteriole—type 2 diabetes mellitus	0.0039	0.0912	CbGeAlD
Paroxetine—TACR1—nerve—type 2 diabetes mellitus	0.00385	0.0901	CbGeAlD
Paroxetine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00278	0.065	CbGeAlD
Paroxetine—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00248	0.0581	CbGeAlD
Paroxetine—SLC6A3—nerve—type 2 diabetes mellitus	0.00194	0.0453	CbGeAlD
Paroxetine—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.00167	0.0391	CbGeAlD
Paroxetine—SLC6A2—nerve—type 2 diabetes mellitus	0.00156	0.0366	CbGeAlD
Paroxetine—HTR2A—hindlimb—type 2 diabetes mellitus	0.00154	0.0361	CbGeAlD
Paroxetine—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.0012	0.0282	CbGeAlD
Paroxetine—TACR1—adipose tissue—type 2 diabetes mellitus	0.00119	0.0278	CbGeAlD
Paroxetine—HTR2A—artery—type 2 diabetes mellitus	0.000946	0.0221	CbGeAlD
Paroxetine—HTR2A—nerve—type 2 diabetes mellitus	0.000939	0.022	CbGeAlD
Paroxetine—HTR2A—endothelium—type 2 diabetes mellitus	0.000799	0.0187	CbGeAlD
Paroxetine—CHRM2—cardiovascular system—type 2 diabetes mellitus	0.00068	0.0159	CbGeAlD
Paroxetine—CHRM1—cardiovascular system—type 2 diabetes mellitus	0.000619	0.0145	CbGeAlD
Paroxetine—CHRM3—kidney—type 2 diabetes mellitus	0.000542	0.0127	CbGeAlD
Paroxetine—CHRM3—adipose tissue—type 2 diabetes mellitus	0.000489	0.0114	CbGeAlD
Paroxetine—CYP2B6—nephron tubule—type 2 diabetes mellitus	0.000449	0.0105	CbGeAlD
Paroxetine—CYP2C8—kidney—type 2 diabetes mellitus	0.00044	0.0103	CbGeAlD
Paroxetine—CYP2B6—cardiovascular system—type 2 diabetes mellitus	0.000403	0.00944	CbGeAlD
Paroxetine—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000399	0.00934	CbGeAlD
Paroxetine—CYP2B6—kidney—type 2 diabetes mellitus	0.000394	0.00923	CbGeAlD
Paroxetine—HTR2A—retina—type 2 diabetes mellitus	0.000389	0.0091	CbGeAlD
Paroxetine—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000329	0.0077	CbGeAlD
Paroxetine—HTR2A—kidney—type 2 diabetes mellitus	0.000322	0.00753	CbGeAlD
Paroxetine—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000298	0.00697	CbGeAlD
Paroxetine—CYP2D6—kidney—type 2 diabetes mellitus	0.000293	0.00686	CbGeAlD
Paroxetine—CYP2C8—liver—type 2 diabetes mellitus	0.000278	0.00651	CbGeAlD
Paroxetine—ABCB1—retina—type 2 diabetes mellitus	0.000255	0.00596	CbGeAlD
Paroxetine—CYP2B6—liver—type 2 diabetes mellitus	0.000249	0.00584	CbGeAlD
Paroxetine—CYP2C9—liver—type 2 diabetes mellitus	0.000247	0.00578	CbGeAlD
Paroxetine—ABCB1—nephron tubule—type 2 diabetes mellitus	0.00024	0.00561	CbGeAlD
Paroxetine—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000215	0.00504	CbGeAlD
Paroxetine—ABCB1—kidney—type 2 diabetes mellitus	0.000211	0.00493	CbGeAlD
Paroxetine—ABCB1—pancreas—type 2 diabetes mellitus	0.000209	0.0049	CbGeAlD
Paroxetine—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000205	0.00481	CbGeAlD
Paroxetine—HTR2A—liver—type 2 diabetes mellitus	0.000203	0.00476	CbGeAlD
Paroxetine—ABCB1—adipose tissue—type 2 diabetes mellitus	0.00019	0.00445	CbGeAlD
Paroxetine—CYP2D6—liver—type 2 diabetes mellitus	0.000185	0.00434	CbGeAlD
Paroxetine—ABCB1—liver—type 2 diabetes mellitus	0.000133	0.00312	CbGeAlD
Paroxetine—Anxiety—Irbesartan—type 2 diabetes mellitus	6.06e-05	0.000236	CcSEcCtD
Paroxetine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.06e-05	0.000236	CcSEcCtD
Paroxetine—Nervous system disorder—Metformin—type 2 diabetes mellitus	6.06e-05	0.000236	CcSEcCtD
Paroxetine—Thrombocytopenia—Metformin—type 2 diabetes mellitus	6.05e-05	0.000236	CcSEcCtD
Paroxetine—Dyspnoea—Valsartan—type 2 diabetes mellitus	6.05e-05	0.000236	CcSEcCtD
Paroxetine—Vertigo—Losartan—type 2 diabetes mellitus	6.04e-05	0.000236	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	6.04e-05	0.000236	CcSEcCtD
Paroxetine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	6.04e-05	0.000236	CcSEcCtD
Paroxetine—Somnolence—Valsartan—type 2 diabetes mellitus	6.03e-05	0.000235	CcSEcCtD
Paroxetine—Syncope—Losartan—type 2 diabetes mellitus	6.03e-05	0.000235	CcSEcCtD
Paroxetine—Paraesthesia—Orlistat—type 2 diabetes mellitus	6.02e-05	0.000235	CcSEcCtD
Paroxetine—Leukopenia—Losartan—type 2 diabetes mellitus	6.02e-05	0.000235	CcSEcCtD
Paroxetine—Discomfort—Irbesartan—type 2 diabetes mellitus	6.01e-05	0.000234	CcSEcCtD
Paroxetine—Skin disorder—Metformin—type 2 diabetes mellitus	6e-05	0.000234	CcSEcCtD
Paroxetine—Immune system disorder—Ramipril—type 2 diabetes mellitus	5.98e-05	0.000233	CcSEcCtD
Paroxetine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	5.97e-05	0.000233	CcSEcCtD
Paroxetine—Dyspepsia—Valsartan—type 2 diabetes mellitus	5.97e-05	0.000233	CcSEcCtD
Paroxetine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	5.97e-05	0.000233	CcSEcCtD
Paroxetine—Dizziness—Bromocriptine—type 2 diabetes mellitus	5.95e-05	0.000232	CcSEcCtD
Paroxetine—Dry mouth—Irbesartan—type 2 diabetes mellitus	5.95e-05	0.000232	CcSEcCtD
Paroxetine—Palpitations—Losartan—type 2 diabetes mellitus	5.94e-05	0.000232	CcSEcCtD
Paroxetine—Nausea—Glimepiride—type 2 diabetes mellitus	5.92e-05	0.000231	CcSEcCtD
Paroxetine—Arrhythmia—Ramipril—type 2 diabetes mellitus	5.91e-05	0.000231	CcSEcCtD
Paroxetine—Loss of consciousness—Losartan—type 2 diabetes mellitus	5.91e-05	0.00023	CcSEcCtD
Paroxetine—Nausea—Sitagliptin—type 2 diabetes mellitus	5.9e-05	0.00023	CcSEcCtD
Paroxetine—Dyspepsia—Orlistat—type 2 diabetes mellitus	5.9e-05	0.00023	CcSEcCtD
Paroxetine—Asthenia—Glyburide—type 2 diabetes mellitus	5.9e-05	0.00023	CcSEcCtD
Paroxetine—Decreased appetite—Valsartan—type 2 diabetes mellitus	5.9e-05	0.00023	CcSEcCtD
Paroxetine—Cough—Losartan—type 2 diabetes mellitus	5.87e-05	0.000229	CcSEcCtD
Paroxetine—Urticaria—Gliclazide—type 2 diabetes mellitus	5.86e-05	0.000229	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	5.86e-05	0.000228	CcSEcCtD
Paroxetine—Alopecia—Ramipril—type 2 diabetes mellitus	5.85e-05	0.000228	CcSEcCtD
Paroxetine—Fatigue—Valsartan—type 2 diabetes mellitus	5.85e-05	0.000228	CcSEcCtD
Paroxetine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	5.84e-05	0.000228	CcSEcCtD
Paroxetine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	5.84e-05	0.000228	CcSEcCtD
Paroxetine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	5.83e-05	0.000227	CcSEcCtD
Paroxetine—Oedema—Irbesartan—type 2 diabetes mellitus	5.83e-05	0.000227	CcSEcCtD
Paroxetine—Decreased appetite—Orlistat—type 2 diabetes mellitus	5.83e-05	0.000227	CcSEcCtD
Paroxetine—Pruritus—Glyburide—type 2 diabetes mellitus	5.82e-05	0.000227	CcSEcCtD
Paroxetine—Mental disorder—Ramipril—type 2 diabetes mellitus	5.8e-05	0.000226	CcSEcCtD
Paroxetine—Constipation—Valsartan—type 2 diabetes mellitus	5.8e-05	0.000226	CcSEcCtD
Paroxetine—Infection—Irbesartan—type 2 diabetes mellitus	5.79e-05	0.000226	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	5.79e-05	0.000226	CcSEcCtD
Paroxetine—Fatigue—Orlistat—type 2 diabetes mellitus	5.78e-05	0.000225	CcSEcCtD
Paroxetine—Hypotension—Metformin—type 2 diabetes mellitus	5.77e-05	0.000225	CcSEcCtD
Paroxetine—Malnutrition—Ramipril—type 2 diabetes mellitus	5.76e-05	0.000225	CcSEcCtD
Paroxetine—Erythema—Ramipril—type 2 diabetes mellitus	5.76e-05	0.000225	CcSEcCtD
Paroxetine—Shock—Irbesartan—type 2 diabetes mellitus	5.73e-05	0.000224	CcSEcCtD
Paroxetine—Pain—Orlistat—type 2 diabetes mellitus	5.73e-05	0.000224	CcSEcCtD
Paroxetine—Arthralgia—Losartan—type 2 diabetes mellitus	5.72e-05	0.000223	CcSEcCtD
Paroxetine—Chest pain—Losartan—type 2 diabetes mellitus	5.72e-05	0.000223	CcSEcCtD
Paroxetine—Myalgia—Losartan—type 2 diabetes mellitus	5.72e-05	0.000223	CcSEcCtD
Paroxetine—Vomiting—Bromocriptine—type 2 diabetes mellitus	5.72e-05	0.000223	CcSEcCtD
Paroxetine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.000223	CcSEcCtD
Paroxetine—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	5.71e-05	0.000223	CcSEcCtD
Paroxetine—Anxiety—Losartan—type 2 diabetes mellitus	5.7e-05	0.000222	CcSEcCtD
Paroxetine—Tachycardia—Irbesartan—type 2 diabetes mellitus	5.69e-05	0.000222	CcSEcCtD
Paroxetine—Rash—Bromocriptine—type 2 diabetes mellitus	5.67e-05	0.000221	CcSEcCtD
Paroxetine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	5.67e-05	0.000221	CcSEcCtD
Paroxetine—Skin disorder—Irbesartan—type 2 diabetes mellitus	5.66e-05	0.000221	CcSEcCtD
Paroxetine—Tension—Ramipril—type 2 diabetes mellitus	5.66e-05	0.000221	CcSEcCtD
Paroxetine—Discomfort—Losartan—type 2 diabetes mellitus	5.65e-05	0.000221	CcSEcCtD
Paroxetine—Dysgeusia—Ramipril—type 2 diabetes mellitus	5.64e-05	0.00022	CcSEcCtD
Paroxetine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	5.63e-05	0.00022	CcSEcCtD
Paroxetine—Headache—Bromocriptine—type 2 diabetes mellitus	5.63e-05	0.00022	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	5.63e-05	0.00022	CcSEcCtD
Paroxetine—Diarrhoea—Glyburide—type 2 diabetes mellitus	5.63e-05	0.000219	CcSEcCtD
Paroxetine—Nervousness—Ramipril—type 2 diabetes mellitus	5.6e-05	0.000218	CcSEcCtD
Paroxetine—Dry mouth—Losartan—type 2 diabetes mellitus	5.6e-05	0.000218	CcSEcCtD
Paroxetine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	5.55e-05	0.000216	CcSEcCtD
Paroxetine—Paraesthesia—Metformin—type 2 diabetes mellitus	5.55e-05	0.000216	CcSEcCtD
Paroxetine—Muscle spasms—Ramipril—type 2 diabetes mellitus	5.54e-05	0.000216	CcSEcCtD
Paroxetine—Confusional state—Losartan—type 2 diabetes mellitus	5.53e-05	0.000216	CcSEcCtD
Paroxetine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	5.52e-05	0.000215	CcSEcCtD
Paroxetine—Dyspnoea—Metformin—type 2 diabetes mellitus	5.51e-05	0.000215	CcSEcCtD
Paroxetine—Somnolence—Metformin—type 2 diabetes mellitus	5.49e-05	0.000214	CcSEcCtD
Paroxetine—Oedema—Losartan—type 2 diabetes mellitus	5.49e-05	0.000214	CcSEcCtD
Paroxetine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	5.49e-05	0.000214	CcSEcCtD
Paroxetine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	5.48e-05	0.000214	CcSEcCtD
Paroxetine—Infection—Losartan—type 2 diabetes mellitus	5.45e-05	0.000213	CcSEcCtD
Paroxetine—Hypotension—Irbesartan—type 2 diabetes mellitus	5.45e-05	0.000213	CcSEcCtD
Paroxetine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	5.44e-05	0.000212	CcSEcCtD
Paroxetine—Dyspepsia—Metformin—type 2 diabetes mellitus	5.44e-05	0.000212	CcSEcCtD
Paroxetine—Tremor—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000211	CcSEcCtD
Paroxetine—Shock—Losartan—type 2 diabetes mellitus	5.4e-05	0.000211	CcSEcCtD
Paroxetine—Urticaria—Valsartan—type 2 diabetes mellitus	5.39e-05	0.00021	CcSEcCtD
Paroxetine—Nervous system disorder—Losartan—type 2 diabetes mellitus	5.38e-05	0.00021	CcSEcCtD
Paroxetine—Thrombocytopenia—Losartan—type 2 diabetes mellitus	5.37e-05	0.00021	CcSEcCtD
Paroxetine—Decreased appetite—Metformin—type 2 diabetes mellitus	5.37e-05	0.000209	CcSEcCtD
Paroxetine—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.36e-05	0.000209	CcSEcCtD
Paroxetine—Tachycardia—Losartan—type 2 diabetes mellitus	5.35e-05	0.000209	CcSEcCtD
Paroxetine—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	5.35e-05	0.000209	CcSEcCtD
Paroxetine—Nausea—Bromocriptine—type 2 diabetes mellitus	5.34e-05	0.000208	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.33e-05	0.000208	CcSEcCtD
Paroxetine—Fatigue—Metformin—type 2 diabetes mellitus	5.33e-05	0.000208	CcSEcCtD
Paroxetine—Urticaria—Orlistat—type 2 diabetes mellitus	5.32e-05	0.000208	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	5.31e-05	0.000207	CcSEcCtD
Paroxetine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	5.3e-05	0.000207	CcSEcCtD
Paroxetine—Body temperature increased—Orlistat—type 2 diabetes mellitus	5.3e-05	0.000207	CcSEcCtD
Paroxetine—Abdominal pain—Orlistat—type 2 diabetes mellitus	5.3e-05	0.000207	CcSEcCtD
Paroxetine—Asthenia—Gliclazide—type 2 diabetes mellitus	5.3e-05	0.000207	CcSEcCtD
Paroxetine—Agitation—Ramipril—type 2 diabetes mellitus	5.3e-05	0.000207	CcSEcCtD
Paroxetine—Constipation—Metformin—type 2 diabetes mellitus	5.28e-05	0.000206	CcSEcCtD
Paroxetine—Angioedema—Ramipril—type 2 diabetes mellitus	5.27e-05	0.000205	CcSEcCtD
Paroxetine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	5.23e-05	0.000204	CcSEcCtD
Paroxetine—Vomiting—Glyburide—type 2 diabetes mellitus	5.23e-05	0.000204	CcSEcCtD
Paroxetine—Pruritus—Gliclazide—type 2 diabetes mellitus	5.22e-05	0.000204	CcSEcCtD
Paroxetine—Malaise—Ramipril—type 2 diabetes mellitus	5.2e-05	0.000203	CcSEcCtD
Paroxetine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	5.2e-05	0.000203	CcSEcCtD
Paroxetine—Rash—Glyburide—type 2 diabetes mellitus	5.18e-05	0.000202	CcSEcCtD
Paroxetine—Somnolence—Irbesartan—type 2 diabetes mellitus	5.18e-05	0.000202	CcSEcCtD
Paroxetine—Dermatitis—Glyburide—type 2 diabetes mellitus	5.18e-05	0.000202	CcSEcCtD
Paroxetine—Vertigo—Ramipril—type 2 diabetes mellitus	5.18e-05	0.000202	CcSEcCtD
Paroxetine—Syncope—Ramipril—type 2 diabetes mellitus	5.17e-05	0.000202	CcSEcCtD
Paroxetine—Leukopenia—Ramipril—type 2 diabetes mellitus	5.16e-05	0.000201	CcSEcCtD
Paroxetine—Headache—Glyburide—type 2 diabetes mellitus	5.15e-05	0.000201	CcSEcCtD
Paroxetine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	5.13e-05	0.0002	CcSEcCtD
Paroxetine—Hypotension—Losartan—type 2 diabetes mellitus	5.13e-05	0.0002	CcSEcCtD
Paroxetine—Palpitations—Ramipril—type 2 diabetes mellitus	5.09e-05	0.000199	CcSEcCtD
Paroxetine—Feeling abnormal—Metformin—type 2 diabetes mellitus	5.09e-05	0.000199	CcSEcCtD
Paroxetine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.07e-05	0.000198	CcSEcCtD
Paroxetine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.07e-05	0.000198	CcSEcCtD
Paroxetine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.05e-05	0.000197	CcSEcCtD
Paroxetine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.05e-05	0.000197	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.03e-05	0.000196	CcSEcCtD
Paroxetine—Cough—Ramipril—type 2 diabetes mellitus	5.03e-05	0.000196	CcSEcCtD
Paroxetine—Fatigue—Irbesartan—type 2 diabetes mellitus	5.03e-05	0.000196	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5e-05	0.000195	CcSEcCtD
Paroxetine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5e-05	0.000195	CcSEcCtD
Paroxetine—Convulsion—Ramipril—type 2 diabetes mellitus	4.99e-05	0.000195	CcSEcCtD
Paroxetine—Pain—Irbesartan—type 2 diabetes mellitus	4.98e-05	0.000194	CcSEcCtD
Paroxetine—Constipation—Irbesartan—type 2 diabetes mellitus	4.98e-05	0.000194	CcSEcCtD
Paroxetine—Insomnia—Losartan—type 2 diabetes mellitus	4.96e-05	0.000194	CcSEcCtD
Paroxetine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	4.94e-05	0.000193	CcSEcCtD
Paroxetine—Paraesthesia—Losartan—type 2 diabetes mellitus	4.93e-05	0.000192	CcSEcCtD
Paroxetine—Urticaria—Metformin—type 2 diabetes mellitus	4.91e-05	0.000191	CcSEcCtD
Paroxetine—Myalgia—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000191	CcSEcCtD
Paroxetine—Arthralgia—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000191	CcSEcCtD
Paroxetine—Chest pain—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000191	CcSEcCtD
Paroxetine—Dyspnoea—Losartan—type 2 diabetes mellitus	4.89e-05	0.000191	CcSEcCtD
Paroxetine—Anxiety—Ramipril—type 2 diabetes mellitus	4.89e-05	0.000191	CcSEcCtD
Paroxetine—Nausea—Glyburide—type 2 diabetes mellitus	4.88e-05	0.000191	CcSEcCtD
Paroxetine—Abdominal pain—Metformin—type 2 diabetes mellitus	4.88e-05	0.000191	CcSEcCtD
Paroxetine—Dizziness—Gliclazide—type 2 diabetes mellitus	4.88e-05	0.00019	CcSEcCtD
Paroxetine—Somnolence—Losartan—type 2 diabetes mellitus	4.88e-05	0.00019	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	4.87e-05	0.00019	CcSEcCtD
Paroxetine—Asthenia—Valsartan—type 2 diabetes mellitus	4.87e-05	0.00019	CcSEcCtD
Paroxetine—Discomfort—Ramipril—type 2 diabetes mellitus	4.85e-05	0.000189	CcSEcCtD
Paroxetine—Dyspepsia—Losartan—type 2 diabetes mellitus	4.83e-05	0.000188	CcSEcCtD
Paroxetine—Asthenia—Orlistat—type 2 diabetes mellitus	4.81e-05	0.000188	CcSEcCtD
Paroxetine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	4.8e-05	0.000187	CcSEcCtD
Paroxetine—Pruritus—Valsartan—type 2 diabetes mellitus	4.8e-05	0.000187	CcSEcCtD
Paroxetine—Dry mouth—Ramipril—type 2 diabetes mellitus	4.8e-05	0.000187	CcSEcCtD
Paroxetine—Decreased appetite—Losartan—type 2 diabetes mellitus	4.77e-05	0.000186	CcSEcCtD
Paroxetine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	4.77e-05	0.000186	CcSEcCtD
Paroxetine—Confusional state—Ramipril—type 2 diabetes mellitus	4.74e-05	0.000185	CcSEcCtD
Paroxetine—Pruritus—Orlistat—type 2 diabetes mellitus	4.74e-05	0.000185	CcSEcCtD
Paroxetine—Fatigue—Losartan—type 2 diabetes mellitus	4.73e-05	0.000185	CcSEcCtD
Paroxetine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	4.7e-05	0.000184	CcSEcCtD
Paroxetine—Oedema—Ramipril—type 2 diabetes mellitus	4.7e-05	0.000184	CcSEcCtD
Paroxetine—Vomiting—Gliclazide—type 2 diabetes mellitus	4.69e-05	0.000183	CcSEcCtD
Paroxetine—Constipation—Losartan—type 2 diabetes mellitus	4.69e-05	0.000183	CcSEcCtD
Paroxetine—Pain—Losartan—type 2 diabetes mellitus	4.69e-05	0.000183	CcSEcCtD
Paroxetine—Rash—Gliclazide—type 2 diabetes mellitus	4.65e-05	0.000182	CcSEcCtD
Paroxetine—Dermatitis—Gliclazide—type 2 diabetes mellitus	4.65e-05	0.000181	CcSEcCtD
Paroxetine—Diarrhoea—Valsartan—type 2 diabetes mellitus	4.64e-05	0.000181	CcSEcCtD
Paroxetine—Urticaria—Irbesartan—type 2 diabetes mellitus	4.63e-05	0.000181	CcSEcCtD
Paroxetine—Shock—Ramipril—type 2 diabetes mellitus	4.63e-05	0.000181	CcSEcCtD
Paroxetine—Headache—Gliclazide—type 2 diabetes mellitus	4.62e-05	0.00018	CcSEcCtD
Paroxetine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	4.61e-05	0.00018	CcSEcCtD
Paroxetine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	4.61e-05	0.00018	CcSEcCtD
Paroxetine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	4.61e-05	0.00018	CcSEcCtD
Paroxetine—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	4.61e-05	0.00018	CcSEcCtD
Paroxetine—Tachycardia—Ramipril—type 2 diabetes mellitus	4.59e-05	0.000179	CcSEcCtD
Paroxetine—Diarrhoea—Orlistat—type 2 diabetes mellitus	4.59e-05	0.000179	CcSEcCtD
Paroxetine—Skin disorder—Ramipril—type 2 diabetes mellitus	4.57e-05	0.000178	CcSEcCtD
Paroxetine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	4.55e-05	0.000177	CcSEcCtD
Paroxetine—Feeling abnormal—Losartan—type 2 diabetes mellitus	4.52e-05	0.000176	CcSEcCtD
Paroxetine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.49e-05	0.000175	CcSEcCtD
Paroxetine—Dizziness—Valsartan—type 2 diabetes mellitus	4.49e-05	0.000175	CcSEcCtD
Paroxetine—Dizziness—Orlistat—type 2 diabetes mellitus	4.43e-05	0.000173	CcSEcCtD
Paroxetine—Asthenia—Metformin—type 2 diabetes mellitus	4.43e-05	0.000173	CcSEcCtD
Paroxetine—Hypotension—Ramipril—type 2 diabetes mellitus	4.4e-05	0.000171	CcSEcCtD
Paroxetine—Nausea—Gliclazide—type 2 diabetes mellitus	4.39e-05	0.000171	CcSEcCtD
Paroxetine—Pruritus—Metformin—type 2 diabetes mellitus	4.37e-05	0.00017	CcSEcCtD
Paroxetine—Urticaria—Losartan—type 2 diabetes mellitus	4.36e-05	0.00017	CcSEcCtD
Paroxetine—Abdominal pain—Losartan—type 2 diabetes mellitus	4.34e-05	0.000169	CcSEcCtD
Paroxetine—Body temperature increased—Losartan—type 2 diabetes mellitus	4.34e-05	0.000169	CcSEcCtD
Paroxetine—Vomiting—Valsartan—type 2 diabetes mellitus	4.31e-05	0.000168	CcSEcCtD
Paroxetine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.29e-05	0.000168	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.29e-05	0.000167	CcSEcCtD
Paroxetine—Rash—Valsartan—type 2 diabetes mellitus	4.28e-05	0.000167	CcSEcCtD
Paroxetine—Dermatitis—Valsartan—type 2 diabetes mellitus	4.27e-05	0.000167	CcSEcCtD
Paroxetine—Vomiting—Orlistat—type 2 diabetes mellitus	4.26e-05	0.000166	CcSEcCtD
Paroxetine—Insomnia—Ramipril—type 2 diabetes mellitus	4.25e-05	0.000166	CcSEcCtD
Paroxetine—Headache—Valsartan—type 2 diabetes mellitus	4.25e-05	0.000166	CcSEcCtD
Paroxetine—Diarrhoea—Metformin—type 2 diabetes mellitus	4.23e-05	0.000165	CcSEcCtD
Paroxetine—Rash—Orlistat—type 2 diabetes mellitus	4.23e-05	0.000165	CcSEcCtD
Paroxetine—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.22e-05	0.000165	CcSEcCtD
Paroxetine—Dermatitis—Orlistat—type 2 diabetes mellitus	4.22e-05	0.000165	CcSEcCtD
Paroxetine—Headache—Orlistat—type 2 diabetes mellitus	4.2e-05	0.000164	CcSEcCtD
Paroxetine—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.19e-05	0.000164	CcSEcCtD
Paroxetine—Asthenia—Irbesartan—type 2 diabetes mellitus	4.18e-05	0.000163	CcSEcCtD
Paroxetine—Somnolence—Ramipril—type 2 diabetes mellitus	4.18e-05	0.000163	CcSEcCtD
Paroxetine—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.14e-05	0.000162	CcSEcCtD
Paroxetine—Pruritus—Irbesartan—type 2 diabetes mellitus	4.12e-05	0.000161	CcSEcCtD
Paroxetine—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.09e-05	0.00016	CcSEcCtD
Paroxetine—Dizziness—Metformin—type 2 diabetes mellitus	4.08e-05	0.000159	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.06e-05	0.000158	CcSEcCtD
Paroxetine—Fatigue—Ramipril—type 2 diabetes mellitus	4.06e-05	0.000158	CcSEcCtD
Paroxetine—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.04e-05	0.000158	CcSEcCtD
Paroxetine—Nausea—Valsartan—type 2 diabetes mellitus	4.03e-05	0.000157	CcSEcCtD
Paroxetine—Constipation—Ramipril—type 2 diabetes mellitus	4.02e-05	0.000157	CcSEcCtD
Paroxetine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.99e-05	0.000156	CcSEcCtD
Paroxetine—Nausea—Orlistat—type 2 diabetes mellitus	3.98e-05	0.000155	CcSEcCtD
Paroxetine—Asthenia—Losartan—type 2 diabetes mellitus	3.94e-05	0.000154	CcSEcCtD
Paroxetine—Vomiting—Metformin—type 2 diabetes mellitus	3.93e-05	0.000153	CcSEcCtD
Paroxetine—Rash—Metformin—type 2 diabetes mellitus	3.89e-05	0.000152	CcSEcCtD
Paroxetine—Dermatitis—Metformin—type 2 diabetes mellitus	3.89e-05	0.000152	CcSEcCtD
Paroxetine—Pruritus—Losartan—type 2 diabetes mellitus	3.88e-05	0.000151	CcSEcCtD
Paroxetine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.88e-05	0.000151	CcSEcCtD
Paroxetine—Headache—Metformin—type 2 diabetes mellitus	3.87e-05	0.000151	CcSEcCtD
Paroxetine—Dizziness—Irbesartan—type 2 diabetes mellitus	3.85e-05	0.00015	CcSEcCtD
Paroxetine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.85e-05	0.00015	CcSEcCtD
Paroxetine—Diarrhoea—Losartan—type 2 diabetes mellitus	3.75e-05	0.000146	CcSEcCtD
Paroxetine—Urticaria—Ramipril—type 2 diabetes mellitus	3.74e-05	0.000146	CcSEcCtD
Paroxetine—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.72e-05	0.000145	CcSEcCtD
Paroxetine—Body temperature increased—Ramipril—type 2 diabetes mellitus	3.72e-05	0.000145	CcSEcCtD
Paroxetine—Vomiting—Irbesartan—type 2 diabetes mellitus	3.71e-05	0.000145	CcSEcCtD
Paroxetine—Rash—Irbesartan—type 2 diabetes mellitus	3.68e-05	0.000143	CcSEcCtD
Paroxetine—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.67e-05	0.000143	CcSEcCtD
Paroxetine—Nausea—Metformin—type 2 diabetes mellitus	3.67e-05	0.000143	CcSEcCtD
Paroxetine—Headache—Irbesartan—type 2 diabetes mellitus	3.65e-05	0.000142	CcSEcCtD
Paroxetine—Dizziness—Losartan—type 2 diabetes mellitus	3.63e-05	0.000142	CcSEcCtD
Paroxetine—Vomiting—Losartan—type 2 diabetes mellitus	3.49e-05	0.000136	CcSEcCtD
Paroxetine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.47e-05	0.000135	CcSEcCtD
Paroxetine—Nausea—Irbesartan—type 2 diabetes mellitus	3.46e-05	0.000135	CcSEcCtD
Paroxetine—Rash—Losartan—type 2 diabetes mellitus	3.46e-05	0.000135	CcSEcCtD
Paroxetine—Dermatitis—Losartan—type 2 diabetes mellitus	3.46e-05	0.000135	CcSEcCtD
Paroxetine—Headache—Losartan—type 2 diabetes mellitus	3.44e-05	0.000134	CcSEcCtD
Paroxetine—Asthenia—Ramipril—type 2 diabetes mellitus	3.37e-05	0.000132	CcSEcCtD
Paroxetine—Pruritus—Ramipril—type 2 diabetes mellitus	3.33e-05	0.00013	CcSEcCtD
Paroxetine—Nausea—Losartan—type 2 diabetes mellitus	3.26e-05	0.000127	CcSEcCtD
Paroxetine—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.22e-05	0.000126	CcSEcCtD
Paroxetine—Dizziness—Ramipril—type 2 diabetes mellitus	3.11e-05	0.000121	CcSEcCtD
Paroxetine—Vomiting—Ramipril—type 2 diabetes mellitus	2.99e-05	0.000117	CcSEcCtD
Paroxetine—Rash—Ramipril—type 2 diabetes mellitus	2.97e-05	0.000116	CcSEcCtD
Paroxetine—Dermatitis—Ramipril—type 2 diabetes mellitus	2.96e-05	0.000116	CcSEcCtD
Paroxetine—Headache—Ramipril—type 2 diabetes mellitus	2.95e-05	0.000115	CcSEcCtD
Paroxetine—Nausea—Ramipril—type 2 diabetes mellitus	2.79e-05	0.000109	CcSEcCtD
Paroxetine—HTR2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.29e-06	3.5e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CALM1—type 2 diabetes mellitus	4.29e-06	3.49e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.28e-06	3.49e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.28e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—type 2 diabetes mellitus	4.28e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.27e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.26e-06	3.47e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.26e-06	3.47e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.26e-06	3.46e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.25e-06	3.46e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—INS—type 2 diabetes mellitus	4.25e-06	3.46e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	4.24e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	4.23e-06	3.44e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOA1—type 2 diabetes mellitus	4.23e-06	3.44e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.22e-06	3.43e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	4.21e-06	3.43e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.21e-06	3.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.21e-06	3.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	4.2e-06	3.42e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.19e-06	3.41e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.19e-06	3.41e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.18e-06	3.41e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RELA—type 2 diabetes mellitus	4.18e-06	3.4e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.17e-06	3.4e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	4.17e-06	3.39e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	4.17e-06	3.39e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	4.16e-06	3.38e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	4.16e-06	3.38e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.14e-06	3.37e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	4.13e-06	3.36e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.13e-06	3.36e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.13e-06	3.36e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.12e-06	3.36e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	4.12e-06	3.35e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	4.12e-06	3.35e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	4.11e-06	3.35e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.11e-06	3.34e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	4.1e-06	3.34e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.07e-06	3.31e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	4.06e-06	3.3e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	4.05e-06	3.3e-05	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.97e-06	3.23e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.95e-06	3.22e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	3.94e-06	3.21e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.93e-06	3.2e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.93e-06	3.2e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.92e-06	3.19e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.91e-06	3.18e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.9e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	3.9e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	3.89e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	3.89e-06	3.17e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.88e-06	3.16e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	3.88e-06	3.16e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	3.86e-06	3.14e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.86e-06	3.14e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	3.84e-06	3.13e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	3.83e-06	3.12e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	3.83e-06	3.11e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	3.82e-06	3.11e-05	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.8e-06	3.09e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	3.79e-06	3.09e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.77e-06	3.07e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	3.76e-06	3.06e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.74e-06	3.05e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.74e-06	3.04e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—type 2 diabetes mellitus	3.73e-06	3.03e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	3.72e-06	3.03e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	3.72e-06	3.03e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.72e-06	3.03e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.72e-06	3.03e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	3.71e-06	3.02e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.71e-06	3.02e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	3.7e-06	3.01e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	3.68e-06	3e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	3.68e-06	3e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.68e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.67e-06	2.99e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	3.67e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—INS—type 2 diabetes mellitus	3.65e-06	2.97e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	3.63e-06	2.96e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	3.62e-06	2.95e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	3.61e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.61e-06	2.93e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	3.58e-06	2.92e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	3.58e-06	2.92e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	3.58e-06	2.91e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	3.58e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	3.56e-06	2.9e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.56e-06	2.9e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	3.55e-06	2.89e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	3.55e-06	2.89e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	3.53e-06	2.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.52e-06	2.87e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.52e-06	2.87e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	3.52e-06	2.86e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	3.52e-06	2.86e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.51e-06	2.85e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.49e-06	2.84e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	3.47e-06	2.83e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.46e-06	2.82e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.46e-06	2.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.46e-06	2.82e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	3.46e-06	2.82e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.45e-06	2.81e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.45e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.45e-06	2.8e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.44e-06	2.8e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	3.44e-06	2.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.43e-06	2.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.43e-06	2.79e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	3.43e-06	2.79e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.43e-06	2.79e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SRC—type 2 diabetes mellitus	3.43e-06	2.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.42e-06	2.78e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	3.41e-06	2.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.4e-06	2.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.4e-06	2.77e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	3.39e-06	2.76e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.38e-06	2.75e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	3.37e-06	2.74e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—type 2 diabetes mellitus	3.35e-06	2.73e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	3.34e-06	2.72e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.34e-06	2.72e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	3.33e-06	2.71e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	3.32e-06	2.71e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	3.3e-06	2.68e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.29e-06	2.68e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SRC—type 2 diabetes mellitus	3.28e-06	2.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.27e-06	2.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.26e-06	2.65e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.23e-06	2.63e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	3.22e-06	2.62e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3R1—type 2 diabetes mellitus	3.2e-06	2.61e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NOS3—type 2 diabetes mellitus	3.2e-06	2.61e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.2e-06	2.6e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	3.19e-06	2.6e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	3.17e-06	2.58e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	3.17e-06	2.58e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	3.15e-06	2.57e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	3.15e-06	2.57e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.14e-06	2.56e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.14e-06	2.56e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	3.13e-06	2.55e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.12e-06	2.54e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.12e-06	2.54e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	3.12e-06	2.54e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.11e-06	2.53e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.11e-06	2.53e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	3.11e-06	2.53e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	3.09e-06	2.52e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.08e-06	2.51e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.08e-06	2.51e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.06e-06	2.49e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	3.03e-06	2.47e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	3.01e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	3e-06	2.44e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	2.98e-06	2.43e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	2.97e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	2.96e-06	2.41e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.96e-06	2.41e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	2.95e-06	2.4e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.94e-06	2.39e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	2.94e-06	2.39e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.93e-06	2.39e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	2.93e-06	2.39e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—type 2 diabetes mellitus	2.93e-06	2.39e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	2.91e-06	2.37e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	2.9e-06	2.36e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.88e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	2.84e-06	2.31e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	2.75e-06	2.24e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	2.71e-06	2.21e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	2.71e-06	2.21e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—INS—type 2 diabetes mellitus	2.69e-06	2.19e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.69e-06	2.19e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.68e-06	2.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.67e-06	2.17e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.67e-06	2.17e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.65e-06	2.16e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.65e-06	2.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.64e-06	2.15e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.64e-06	2.15e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.64e-06	2.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.63e-06	2.14e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.62e-06	2.13e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.6e-06	2.12e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	2.59e-06	2.11e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	2.57e-06	2.09e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	2.54e-06	2.07e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.52e-06	2.05e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	2.52e-06	2.05e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.51e-06	2.04e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.5e-06	2.03e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.49e-06	2.03e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	2.48e-06	2.02e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.48e-06	2.02e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.47e-06	2.01e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.47e-06	2.01e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	2.47e-06	2.01e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.45e-06	1.99e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.44e-06	1.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.43e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.42e-06	1.97e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.4e-06	1.95e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	2.36e-06	1.92e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	2.36e-06	1.92e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	2.33e-06	1.89e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.32e-06	1.89e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.31e-06	1.88e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	2.31e-06	1.88e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	2.31e-06	1.88e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	2.3e-06	1.87e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	2.28e-06	1.86e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.26e-06	1.84e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.25e-06	1.83e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.24e-06	1.83e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	2.23e-06	1.81e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	2.23e-06	1.81e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.22e-06	1.81e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	2.21e-06	1.8e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	2.21e-06	1.8e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	2.21e-06	1.8e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	2.16e-06	1.76e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.13e-06	1.73e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.08e-06	1.69e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.07e-06	1.68e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.06e-06	1.68e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.04e-06	1.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.04e-06	1.66e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	2.04e-06	1.66e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.04e-06	1.66e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.03e-06	1.65e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	2.02e-06	1.64e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.02e-06	1.64e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2e-06	1.63e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	1.71e-06	1.39e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.57e-06	1.27e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.56e-06	1.27e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.55e-06	1.26e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.54e-06	1.25e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—type 2 diabetes mellitus	1.47e-06	1.2e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.44e-06	1.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.44e-06	1.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.43e-06	1.17e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.42e-06	1.15e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	1.25e-06	1.01e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	1.09e-06	8.84e-06	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.02e-06	8.33e-06	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	1.01e-06	8.26e-06	CbGpPWpGaD
